Wells Fargo & Company has filed a preliminary pricing supplement for its Medium-Term Notes, Series AA, which is a significant move in its financing strategy. The notes are set to mature in 2036 and will pay a fixed interest rate of 6.00% per annum. This issuance reflects broader trends in the national commercial banking sector, where institutions are actively seeking to optimize their capital structures.
The filing, dated November 13, 2026, indicates that the notes will not be listed on any exchange and are designed to be held to maturity. The company has emphasized that all payments on the notes are subject to its credit risk, meaning that investors could lose some or all of their investment if Wells Fargo defaults on its obligations.
Wells Fargo is a leading national commercial bank, incorporated in Delaware, with a fiscal year ending on December 31. The company operates under the ticker symbol WFC and is listed on the New York Stock Exchange. It has a long history of providing a range of financial services, including banking, investments, and mortgage products.
The preliminary pricing supplement states that the notes will have a term of 10 years, with interest payments made semi-annually. The original offering price for the notes is set at $1,000 per note, with some variations for eligible institutional investors. The notes are redeemable by Wells Fargo in whole but not in part on specified optional redemption dates.
This move may affect various stakeholders, including investors looking for fixed-income opportunities and competitors in the banking sector who may respond with similar offerings. As the market evolves, Wells Fargo's strategy will likely influence how other banks position themselves in terms of capital raising and risk management.
Details were not available in the SEC filing regarding what happens next, but the issuance of these notes indicates Wells Fargo's proactive approach to managing its financing needs in a competitive landscape.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










